Dataset Information

Incorporating LC-MS/MS Analysis and the Dereplication of Natural Product Samples into an Upper-Division Undergraduate Laboratory Course

ABSTRACT: This dataset represents a collection of chromatography fractions derived from botanical extractions. These chromatography fractions were chosen based upon demonstrated antioxidant activity following a standard DPPH assay. Echinacea-1 is the E. angustifolia sample while -2 and -3 were identified as E. purpurea. All collected samples have voucher specimens held in the URI Herbarium.

INSTRUMENT(S): LTQ

ORGANISM(S): Berberis Thunbergii (ncbitaxon:121720) Hypericum Perforatum (ncbitaxon:65561) Actaea Racemosa (ncbitaxon:64040) Sambucus Nigra (ncbitaxon:4202) Echinacea Purpurea (ncbitaxon:53751) Echinacea Angustifolia (ncbitaxon:308558) Salvia Rosmarinus (ncbitaxon:39367) Humulus Lupulus (ncbitaxon:3486) Withania Somnifera (ncbitaxon:126910) Aloe Vera (ncbitaxon:34199)

SUBMITTER: Matt Bertin

PROVIDER: MSV000088444 | MassIVE | Wed Nov 24 12:44:00 GMT 2021

REPOSITORIES: MassIVE

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Intervention 1: ?1st Arm: Short course radiotherapy with 25 Gy in 5 fractions with concurrent chemotherapy regimen including Capecitabine 625mg/m2/bid for 5 days and Oxaliplatin 50mg/m2/day for 1 day then one cycle chemotherapy with XELOX regimen (Capecitabine 1000mg/m2/bid for 14 days and Oxaliplatin 130mg/m2/day for 1 day) 3 - 4 weeks after completion of radiotherapy then surgery at least 8 weeks after the radiotherapy last session. Intervention 2: 2nd Arm (Control): Long course radiotherapy with 50 Gy in 25 fractions with concurrent Capecitabine 825mg/m2/bid for 5 days each week then one cycle chemotherapy with XELOX regimen (Capecitabine 1000mg/m2/bid for 14 days and Oxaliplatin 130mg/m2/day for 1 day) 3 - 4 weeks after completion of radiotherapy then surgery at least 8 weeks after the radiotherapy last session.;Treatment - Drugs;Treatment - Drugs;?1st Arm: Short course radiotherapy with 25 Gy in 5 fractions with concurrent chemotherapy regimen including Capecitabine 625mg/m2/bid for 5 days and Oxaliplatin 50mg/m2/day for 1 day then one cycle chemotherapy with XELOX regimen (Capecitabine 1000mg/m2/bid for 14 days and Oxaliplatin 130mg/m2/day for 1 day) 3 - 4 weeks after completion of radiotherapy then surgery at least 8 weeks after the radiotherapy last session.;2nd Arm (Control): Long course radiotherapy with 50 Gy in 25 fractions with concurrent Capecitabine 825mg/m2/bid for 5 days each week then one cycle chemotherapy with XELOX regimen (Capecitabine 1000mg/m2/bid for 14 days and Oxaliplatin 130mg/m2/day for 1 day) 3 - 4 weeks after completion of radiotherapy then surgery at least 8 weeks after the radiotherapy last session. Primary outcome(s): Complications. Timepoint: At the Initiation of Radiotherapy up to one month after surgery. Method of measurement: Common terminology criteria for cancer related therapy adverse events. Study Design: Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.

Dataset Information

Incorporating LC-MS/MS Analysis and the Dereplication of Natural Product Samples into an Upper-Division Undergraduate Laboratory Course

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets